| Literature DB >> 33267808 |
Jin Sug Kim1, Kyung Hwan Jeong2, Dong Won Lee3, Sam Yeol Lee4, Sang Ho Lee1, Jaeseok Yang5, Curie Ahn6, Hyeon Seok Hwang1.
Abstract
BACKGROUND: As in younger recipients, post-transplant infection is a frequent and devastating complication after kidney transplantation (KT) in older recipients. However, few studies have analyzed characteristics of post-transplant infection in older kidney recipients. In this study of a nation-wide cohort of older kidney recipients, we investigated the current epidemiology, risk factors, and clinical impacts of early post-transplant infection, which was defined as infectious complications requiring hospitalization within the first 6 months after KT.Entities:
Keywords: Infectious complication; Kidney transplantation; Older kidney recipient
Mesh:
Year: 2020 PMID: 33267808 PMCID: PMC7709316 DOI: 10.1186/s12877-020-01859-3
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Baseline characteristics of study sample
| Overall ( | < 60 year-old ( | ≥ 60 year-old ( | p | |
|---|---|---|---|---|
| Age (years) | 48.78 ± 11.50 | 45.53 ± 9.88 | 64.08 ± 3.48 | < 0.001 |
| Sex, female (%) | 1527 (40.9%) | 1287 (41.8%) | 240 (36.5%) | 0.013 |
| Body mass index (kg/m2) | 23.05 ± 3.52 | 22.97 ± 3.61 | 23.41 ± 3.05 | 0.001 |
| Cause of ESRD, n (%) | < 0.001 | |||
| Diabetes mellitus | 870 (23.3%) | 642 (20.8%) | 228 (34.7%) | |
| Hypertension | 612 (16.4%) | 486 (15.8%) | 126 (19.2%) | |
| Glomerulonephritis | 1251 (33.5%) | 1121 (36.4%) | 130 (19.8%) | |
| ADPKD | 172 (4.6%) | 137 (4.4%) | 35 (5.3%) | |
| Others | 123 (3.3%) | 103 (3.3%) | 20 (3.0%) | |
| Unknown | 710 (19.0%) | 592 (19.2%) | 118 (18.0%) | |
| Duration of dialysis (months) | 56.17 ± 64.13 | 47.29 ± 62.77 | 50.73 ± 61.03 | 0.201 |
| Diabetes mellitus, n (%) | 1073 (28.7%) | 778 (25.3%) | 295 (44.9%) | < 0.001 |
| Hypertension, n (%) | 3334 (89.2%) | 2719 (88.3%) | 615 (93.6%) | < 0.001 |
| Cardiovascular disease, n (%) | 404 (10.8%) | 260 (8.4%) | 144 (22.0%) | < 0.001 |
| Hemoglobin (g/dL) | 10.73 ± 1.58 | 10.70 ± 1.59 | 10.88 ± 1.52 | 0.006 |
| Creatinine, baseline (mg/dL) | 8.79 ± 3.36 | 8.96 ± 3.42 | 8.01 ± 2.98 | < 0.001 |
| Creatinine, discharge (mg/dL) | 1.22 ± 0.78 | 1.22 ± 0.79 | 1.21 ± 0.69 | 0.708 |
| Albumin (g/dL) | 3.93 ± 0.52 | 3.93 ± 0.53 | 3.89 ± 0.49 | 0.049 |
| Re-transplantation, n (%) | 289 (7.7%) | 249 (8.1%) | 40 (6.1%) | 0.082 |
| Donor age (years) | 46.44 ± 13.18 | 45.47 ± 12.78 | 50.95 ± 14.05 | < 0.001 |
| Donor sex, female (%) | 1720 (46.0%) | 1437 (46.7%) | 283 (43.1%) | 0.095 |
| Deceased donor, n (%) | 1446 (38.7%) | 1111 (36.1%) | 335 (51.0%) | < 0.001 |
| Desensitization, n (%) | 845 (22.6%) | 723 (23.5%) | 122 (18.6%) | 0.006 |
| ABO incompatibility, n (%) | 586 (15.7%) | 495 (16.1%) | 91 (13.9%) | 0.156 |
| Presence of DSA, n (%) | 230 (6.2%) | 184 (6.0%) | 46 (7.0%) | 0.319 |
| Length of hospitalization after KT (days) | 17.88 ± 10.63 | 17.53 ± 10.35 | 19.56 ± 11.71 | < 0.001 |
| Induction immunosuppression | < 0.001 | |||
| No use, n (%) | 66 (1.8%) | 52 (1.7%) | 14 (2.1%) | |
| Basiliximab, n (%) | 2924 (78.2%) | 2447 (79.4%) | 477 (72.8%) | |
| ATG, n (%) | 668 (17.9%) | 513 (16.7%) | 155 (23.7%) | |
| Basiliximab + ATG, n (%) | 77 (2.1%) | 68 (2.2%) | 9 (1.4%) | |
| Calcineurin inhibitors, n (%) | 0.067 | |||
| No use | 45 (1.2%) | 32 (1.0%) | 13 (2.0%) | |
| Tacrolimus | 3568 (95.5%) | 2952 (95.8%) | 616 (94.0%) | |
| Cyclosporine | 122 (3.3%) | 96 (3.1%) | 26 (4.0%) | |
| Mycophenolate, n (%) | 3399 (90.9%) | 2819 (91.5%) | 580 (88.7%) | 0.021 |
| mTOR inhibitors, n (%) | 48 (1.3%) | 37 (1.2%) | 11 (1.7%) | 0.324 |
| Steroid, n (%) | 3647 (97.6%) | 3011 (97.2%) | 636 (97.2%) | 0.430 |
| Follow-up duration (months) | 27.45 ± 12.47 | 27.95 ± 12.41 | 25.14 ± 12.49 | < 0.001 |
| Early post-transplant infection, n (%) | 670 (17.9%) | 521 (16.9%) | 149 (22.7%) | < 0.001 |
ESRD end stage renal disease, ADPKD autosomal dominant polycystic kidney disease, DSA donor specific antibody, KT kidney transplantation, ATG anti-thymocyte globulin
Fig. 1Frequencies of early post-transplant infection after KT according to time (a, b), causative pathogens (c, d), and sites (e, f). a, c, and e represent younger recipients and b, d, and f represent older recipients. KT, kidney transplantation; PCP, pneumocystis pneumonia; CNS, central nervous system; and GI system, gastrointestinal system
Risk factors for the development of early post-transplant infection in younger recipients
| < 60 year-old | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Sex, female | 1.276 (1.074–1.515) | 0.006 | 1.323 (1.103–1.587) | 0.003 |
| BMI (kg/m2) | 1.017 (0.993–1.041) | 0.173 | ||
| Cause of ESRD | ||||
| Diabetes mellitus | 1 | |||
| Hypertension | 1.007 (0.756–1.341) | 0.964 | ||
| Glomerulonephritis | 1.007 (0.796–1.275) | 0.952 | ||
| ADPKD | 1.100 (0.712–1.700) | 0.666 | ||
| Others | 1.209 (0.761–1.921) | 0.421 | ||
| Unknown | 0.913 (0.691–1.205) | 0.518 | ||
| Duration of dialysis (month) | 1.002 (1.001–1.003) | < 0.001 | 1.000 (0.999–1.002) | 0.377 |
| Diabetes mellitus | 1.015 (0.834–1.237) | 0.879 | ||
| Hypertension | 1.021 (0.779–1.336) | 0.882 | ||
| Cardiovascular disease | 1.520 (1.167–1.980) | 0.002 | 1.454 (1.108–1.906) | 0.007 |
| Creatinine, baseline (mg/dL) | 1.004 (0.979–1.030) | 0.761 | ||
| Creatinine, discharge (mg/dL) | 1.015 (0.916–1.125) | 0.772 | ||
| Re-transplantation | 1.065 (0.782–1.450) | 0.690 | ||
| Deceased donor | 1.553 (1.306–1.846) | < 0.001 | 1.409 (1.120–1.772) | 0.003 |
| Donor age (year) | 1.010 (1.003–1.017) | 0.004 | 1.008 (1.001–1.015) | 0.022 |
| Donor sex, female | 1.346 (1.129–1.604) | 0.001 | 1.192 (0.992–1.433) | 0.061 |
| Desensitization | 1.015 (0.829–1.243) | 0.883 | ||
| ABO incompatibility | 0.757 (0.586–0.979) | 0.034 | 0.934 (0.708–1.230) | 0.626 |
| Presence of DSA | 1.536 (1.128–2.092) | 0.006 | 1.427 (1.016–2.006) | 0.040 |
| Length of hospitalization after KT (day) | 1.015 (1.011–1.020) | < 0.001 | 1.011 (1.006–1.017) | < 0.001 |
| Induction immunosuppression | ||||
| No use | 1 | 1 | ||
| Basiliximab | 2.226 (0.831–5.959) | 0.111 | 2.511 (0.479–8.252) | 0.051 |
| ATG | 2.760 (1.016–7.493) | 0.046 | 2.589 (0.952–7.042) | 0.062 |
| Basiliximab + ATG | 2.894 (0.953–8.793) | 0.061 | 2.337 (0.767–7.118) | 0.135 |
| Calcineurin inhibitors | ||||
| No use | 1 | |||
| Tacrolimus | 1.345 (0.503–3.597) | 0.555 | ||
| Cyclosporine | 1.146 (0.377–3.481) | 0.810 | ||
| Steroid | 1.477 (0.735–2.970) | 0.273 | ||
| Acute rejection | 2.993 (2.499–3.585) | < 0.001 | 2.637 (2.455–3.426) | < 0.001 |
BMI body mass index, ESRD end stage renal disease, ADPKD autosomal dominant polycystic kidney disease, DSA donor specific antibody, KT kidney transplantation, ATG anti-thymocyte globulin
Risk factors for the development of early post-transplant infection in older recipients
| ≥ 60 year-old | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Sex, female | 1.548 (1.119–2.142) | 0.008 | 1.398 (1.199–1.631) | < 0.001 |
| BMI (kg/m2) | 0.991 (0.939–1.046) | 0.741 | ||
| Cause of ESRD | ||||
| Diabetes mellitus | 1 | |||
| Hypertension | 0.898 (0.554–1.454) | 0.661 | ||
| Glomerulonephritis | 1.192 (0.767–1.854) | 0.436 | ||
| ADPKD | 0.781 (0.334–1.823) | 0.568 | ||
| Others | 1.135 (0.452–2.850) | 0.787 | ||
| Unknown | 1.226 (0.778–1.932) | 0.379 | ||
| Duration of dialysis (month) | 1.003 (1.001–1.005) | 0.004 | 1.001 (1.000–1.002) | 0.156 |
| Diabetes mellitus | 0.880 (0.635–1.219) | 0.441 | ||
| Hypertension | 0.663 (0.375–1.172) | 0.157 | ||
| Cardiovascular disease | 0.931 (0.627–1.384) | 0.725 | ||
| Creatinine, baseline (mg/dL) | 0.988 (0.935–1.045) | 0.680 | ||
| Creatinine, discharge (mg/dL) | 1.153 (0.945–1.408) | 0.161 | ||
| Re-transplantation | 0.994 (0.520–1.901) | 0.986 | ||
| Deceased donor | 1.495 (1.076–2.077) | 0.017 | 1.364 (1.137–1.637) | 0.001 |
| Donor age (year) | 1.022 (1.009–1.034) | 0.001 | 1.010 (1.004–1.016) | 0.001 |
| Donor sex, female | 1.204 (0.864–1.677) | 0.273 | ||
| Desensitization | 1.257 (0.849–1.859) | 0.253 | ||
| ABO incompatibility | 1.050 (0.662–1.667) | 0.836 | ||
| Presence of DSA | 1.324 (0.749–2.340) | 0.334 | ||
| Length of hospitalization after KT (day) | 1.016 (1.008–1.025) | < 0.001 | 1.010 (1.006–1.014) | < 0.001 |
| Induction immunosuppression | ||||
| No use | 1 | 1 | ||
| Basiliximab | 1.513 (0.373–6.134) | 0.562 | 2.051 (0.916–4.593) | 0.081 |
| ATG | 2.022 (0.489–8.357) | 0.331 | 2.131 (0.941–4.827) | 0.070 |
| Basiliximab + ATG | 5.087 (0.987–26.223) | 0.052 | 2.138 (0.851–5.370) | 0.106 |
| Calcineurin inhibitors | ||||
| No use | 1 | |||
| Tacrolimus | 3.285 (0.460–23.478) | 0.236 | ||
| Cyclosporine | 0.495 (0.031–7.913) | 0.619 | ||
| Steroid | 0.974 (0.361–2.631) | 0.958 | ||
| Acute rejection | 3.377 (2.399–4.754) | 2.907 (2.471–3.419) | < 0.001 | |
BMI body mass index, ESRD end stage renal disease, ADPKD autosomal dominant polycystic kidney disease, DSA donor specific antibody, KT kidney transplantation, ATG anti-thymocyte globulin
Clinical outcomes according to the presence or absence of early post-transplant infection
| Overall (N = 3738) | < 60 year-old (n = 3081) | ≥ 60 year-old (n = 657) | |||
|---|---|---|---|---|---|
| With infection ( | Without infection ( | With infection ( | Without infection ( | ||
| 49 (1.3%) | 7 (1.3%) | 29 (1.1%) | 2 (1.3%) | 11 (2.2%) | |
| 578 (15.5%) | 133 (25.5%) | 354 (13.8%) | 34 (22.8%) | 57 (11.2%) | |
| 58 (1.6%) | 19 (3.6%) | 30 (1.2%) | 6 (4.0%) | 3 (0.6%) | |
| 59 (1.65) | 21 (4.0%) | 16 (0.6%) | 12 (8.1%) | 10 (2.0%) | |
Fig. 2Event free survival according to early post-transplant infection after kidney transplantation. a, c, e, and g represent younger recipients and b, d, f, and h represent older recipients